Page last updated: 2024-10-24

chlorambucil and Genetic Predisposition

chlorambucil has been researched along with Genetic Predisposition in 2 studies

Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.

Research Excerpts

ExcerptRelevanceReference
"The design of a new personalized anti-breast cancer drug has been explained in the third phase."1.46Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach. ( Iyer, PM; Karthikeyan, S; Krishnan Namboori, PK; Sanjay Kumar, P, 2017)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Iyer, PM1
Karthikeyan, S1
Sanjay Kumar, P1
Krishnan Namboori, PK1
Pearson, TC1
Messinezy, M1

Reviews

1 review available for chlorambucil and Genetic Predisposition

ArticleYear
Idiopathic erythrocytosis, diagnosis and clinical management.
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Aged; Arterial Occlusive Diseases; Bone Marrow; Chlorambucil; Diagnosis, Differential; Endocrine Sys

2001

Other Studies

1 other study available for chlorambucil and Genetic Predisposition

ArticleYear
Comprehensive strategy for the design of precision drugs and identification of genetic signature behind proneness of the disease-a pharmacogenomic approach.
    Functional & integrative genomics, 2017, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; Chlorambucil; Drug Design; Female; Genetic P

2017